Yesterday Moderna received a downgrade from Needham from ‘Buy’ to ‘Hold’ rating. Analysts believe that Moderna's stock is fully valued after capturing an eightfold gain this year.

Tech review: earnings take centre stage as Apple reaches record high
IBM and Groq join forces to revolutionize AI processing
US Defense Industry Preview - Has it reached its peak?
Waymo: Race against the regulators
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.